Boehringer Ingelheim successfully concluded the purchase of Fort Dodge cattle vaccines for its Mexican business
Ingelheim, Germany, 10 August 2010 - Boehringer
Ingelheim, a global pharmaceutical group of companies, together
with its U.S. animal health business, Boehringer Ingelheim
Vetmedica, Inc., announced today that they successfully concluded
the purchase of certain Fort Dodge cattle vaccines for Boehringer
Ingelheim Vetmedica Mexico. This transaction is part of the
acquisition of significant assets of Fort Dodge Animal Health in
2009 and will considerably strengthen the cattle product portfolio
of Boehringer Ingelheim Vetmedica Mexico.
In 2009, Boehringer Ingelheim, together with its U.S. animal health
business, acquired a significant portion of the Fort Dodge Animal
Health business. The acquisition, which included products in the
U.S., Australia, Canada and South Africa, as well as two
manufacturing and research facilities located in Fort Dodge, Iowa,
increased the size of Boehringer Ingelheim's companion animal and
cattle portfolios and strengthened the company's position as a
leading animal vaccine supplier.
The acquired portfolio in Mexico includes the following well known
brands: Presponse®HM, Pyramid® 5, Triangle® 4 (+type 2
BVD), Triangle® 9 + HS and Triangle® 9 (+ type 2 BVD). The
products will continue to reflect the familiar trademarks. The
Managing Director of Boehringer Ingelheim Animal Health in Mexico,
Dr. Francisco Escudero, commented: “Boehringer Ingelheim is
pleased to add these important and popular vaccines to our product
portfolio. We are committed to continue providing our cattle
customers with a comprehensive package of solutions and
services.”
Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 15
leading pharmaceutical companies. Headquartered in Ingelheim,
Germany, it operates globally with 142 affiliates in 50 countries
and more than 41,500 employees. Since it was founded in 1885, the
family-owned company has been committed to researching, developing,
manufacturing and marketing novel products of high therapeutic
value for human and veterinary medicine.
In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro
while spending 21% of net sales in its largest business segment
Prescription Medicines on research and development.